FDA Clearance Tracker · K262516
TSK OptiXion
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Oct 6, 2026
Substantially Equivalent
Time to decision
77 days
Received Jul 21, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K262516
- Device name
- TSK OptiXion
- Applicant
- Tsk Laboratory, Japan
- Applicant location
- Tochigi-Ken, JP
- Received
- Jul 21, 2026
- Decided
- Oct 6, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Ophthalmic Needle (QYM)
- Device class
- Class II
- Regulation
- 21 CFR 880.5570
- Specialty
- Hospital Medicine & Nursing
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QYM. The earliest in FDA's data is K230951, decided Oct 18, 2023.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K262516
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Tsk Laboratory, Japan
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- TSK Syringe510(k)
K250127 · Decided Jul 30, 2025 · 194 days after receipt
Device type: Low Dead Space Piston Syringe (QNQ) · Hospital Medicine & Nursing
- TSK SELECT Needle510(k)
K250284 · Decided Jul 24, 2025 · 174 days after receipt
Device type: Needle, Hypodermic, Single Lumen (FMI) · Hospital Medicine & Nursing
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.